Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00794144 · ClinicalTrials.gov registry record · Phase 2
Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
NCT00794144 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 132 participants.
The verdict
NCT00794144, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics (study of the action of a drug in the body) in these children
Interventions
- DRUG Olopatadine Hydrochloride Nasal Spray 0.6%
- DRUG Olopatadine Hydrochloride Nasal Spray Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00794144
The ClinicalTrials.gov registry entry for NCT00794144 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olopatadine Hydrochloride Nasal Spray 0.6% is the first listed.
NCT00794144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00794144 about?
NCT00794144 is a clinical study titled "Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age". The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to less than 6 who have a history of nasal allergies, and to assess the pharmcokinetics (study of the action of a drug...
What is the current status of trial NCT00794144?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2008-10.
What interventions are being tested in trial NCT00794144?
The interventions under investigation include: Olopatadine Hydrochloride Nasal Spray 0.6% (DRUG), Olopatadine Hydrochloride Nasal Spray Vehicle (DRUG).
Who is sponsoring clinical trial NCT00794144?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.